$145.14
1.30%
Nasdaq, Nov 18, 04:00 pm EST. Closed.
ISIN
US40131M1099
Symbol
GH

Guardant Health, Inc. Stock price

$145.14
-12.74 8.07% 1M
+49.48 51.72% 6M
+43.00 42.10% YTD
+49.57 51.87% 1Y
+121.24 507.28% 3Y
+45.21 45.24% 5Y
+112.94 350.75% 10Y
+112.94 350.75% 20Y
Nasdaq, Closing price Wed, Nov 18 2026
+1.86 1.30%

AI Insights on Guardant Health, Inc. Insights AI Insights on Guardant Health, Inc.

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Is Guardant Health, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,085 stocks worldwide.

Key metrics

Basic
Market capitalization
$19.6b
Enterprise Value
$20.1b
Net debt
$449.5m
Cash
$1.1b
Shares outstanding
133.6m
Valuation
P/E
negative
P/S | estimate
16.6 | 14.0
EV/Sales | estimate
17.0 | 14.3
EV/FCF | ex SBC
negative | negative
P/B
negative
Financial Health
Equity Ratio
-4.9%
Return on Equity
419.2%
ROCE
-29.9%
ROIC
-65.1%
Debt/Equity
-6.7
Share-Based Compensation & Dilution
SBC | % of Revenue
$191.3m | 16.2%
SBC as % of FCF
-
SBC Growth 1Y
15.0%
Share Count Growth 1Y
7.3%
Shareholder Yield
-7.3%
Financials
Revenue | estimate
$1.2b | $1.4b
EBITDA
$-431.8m
EBIT
$-470.3m
Net Income
$-453.4m
Free Cash Flow | ex SBC
$-240.7m | $-432.1m
Growth
Revenue | estimate
42.7% | 43.2%
EBITDA
-3.0%
EBIT
-2.1%
Net Income
-9.6%
Free Cash Flow
11.5%
Margin
Gross
65.0%
EBITDA
-36.5%
EBIT
-39.8%
Net
-38.3%
Free Cash Flow | ex SBC
-20.4% | -36.5%
More
EPS
$-3.4
FCF per Share
$-1.8
Short interest
7.3%
Employees
2k
Rev per Employee
$390.0k

Guardant Health, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

36 Analysts have issued a Guardant Health, Inc. forecast:

33x Buy
92%
3x Hold
8%

Analyst Opinions

36 Analysts have issued a Guardant Health, Inc. forecast:

Buy
92%
Hold
8%

Guardant Health, Inc. Events

Past Events
NOV
5
Q3 2026 Earnings Call
14 days ago
SEP
15
Morgan Stanley 24th Annual Global Healthcare Conference
2 months ago
AUG
12
Canaccord Genuity's 46th Annual Growth Conference
3 months ago
JUL
30
Q2 2026 Earnings Call
4 months ago
MAY
12
Bank of America Global Healthcare Conference 2026
6 months ago
MAY
7
Q1 2026 Earnings Call
7 months ago
MAR
11
Barclays 28th Annual Global Healthcare Conference
8 months ago
FEB
19
Q4 2025 Earnings Call
9 months ago
JAN
12
44th Annual J.P. Morgan Healthcare Conference
10 months ago
OCT
29
Q3 2025 Earnings Call
about one year ago

Financial data from Guardant Health, Inc.

Jun '26
+/-
%
1,183 1,183
43% 43%
100%
- Direct Costs 414 414
34% 34%
35%
769 769
48% 48%
65%
- Selling and Administrative Expenses 864 864
38% 38%
73%
- Research and Development Expense 376 376
5% 5%
32%
-432 -432
3% 3%
-36%
- Depreciation and Amortization 38 38
8% 8%
3%
EBIT (Operating Income) EBIT -470 -470
2% 2%
-40%
Net Profit -453 -453
10% 10%
-38%

In millions USD.

Don't miss a Thing! We will send you all news about Guardant Health, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Guardant Health, Inc. Stock News

Neutral
Business Wire
●
6 days ago
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on October 13, 2026, the Compensation Committee of Guardant's Board of Directors approved the granting of restricted stock units (“RSUs”) representing 86,192 shares of its common stock to 118 new non-executive employees with a grant date of November 9, 2026, under t...
Neutral
Business Wire
●
7 days ago
PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (“Guardant Health”) (Nasdaq: GH), a leading precision oncology company, today announced the pricing of its offering of $500 million aggregate principal amount of 0% convertible senior notes due 2032 (the “notes”) in a private offering (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to...
Neutral
Business Wire
●
8 days ago
PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (“Guardant Health”) (Nasdaq: GH), a leading precision oncology company, today announced its intention to offer $500.0 million aggregate principal amount of convertible senior notes due 2032 (the “notes”) in a private offering (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144...
More Guardant Health, Inc. News

Company Profile

Guardant Health, Inc. is a precision oncology company, which engages in treatment of cancer through use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions include treatment selection, recurrence detection, and early detection. The company was founded by Helmy Eltoukhy, AmirAli H. Talasaz, and Michael Joseph Wiley in 2012 and is headquartered in Redwood City, CA.

Head office United States
CEO Dr. Eltoukhy
Employees 2,498
Founded 2012
Website guardanthealth.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today